Artikkel
ISPOR 2026: perspectives shaping the future of access, evidence, and patient impact
At ISPOR 2026, Cencora experts shared their perspectives on the forces reshaping healthcare decision-making across global markets.
This interview series brings together timely conversations on most-favored-nation (MFN) pricing, international reference pricing (IRP), and launch strategy, alongside the expanding role of artificial intelligence in health economics and outcomes research (HEOR), real-world evidence (RWE), and market access. Across these discussions, one theme remains constant: the need to connect policy, evidence, and innovation more effectively to improve the patient journey and support access to therapy.
This interview series brings together timely conversations on most-favored-nation (MFN) pricing, international reference pricing (IRP), and launch strategy, alongside the expanding role of artificial intelligence in health economics and outcomes research (HEOR), real-world evidence (RWE), and market access. Across these discussions, one theme remains constant: the need to connect policy, evidence, and innovation more effectively to improve the patient journey and support access to therapy.
Pricing pressures & patient access at ISPOR
At ISPOR, Casper Paardekooper, VP, Head of Pricing, Policy and Stakeholder Engagement, Europe, Cencora, shared perspectives on the difficult balance between pharmaceutical economics and patient access. He explained how international pricing pressures can shape launch sequencing decisions, particularly when lower prices in Europe or Japan may put significant U.S. revenue at risk. While these are difficult business realities, he emphasized that delayed launches can ultimately slow patient access to therapies.
Casper also outlined several actions pharmaceutical companies can take, including more strategic launch sequencing, stronger global pricing governance, stronger evidence packages to demonstrate value, and closer collaboration with healthcare stakeholders and industry associations to help address access and spending challenges together.
Casper also outlined several actions pharmaceutical companies can take, including more strategic launch sequencing, stronger global pricing governance, stronger evidence packages to demonstrate value, and closer collaboration with healthcare stakeholders and industry associations to help address access and spending challenges together.
Three signals from ISPOR that biopharma should not ignore
From pricing policy to artificial intelligence (AI) to the patient journey, Chelsey Campbell, Senior Director, Commercial Excellence, Cencora, pointed to three issues that stood out most during conversations at ISPOR. Together, they reflect how quickly the market access landscape is evolving — and how important it is for manufacturers to connect policy, evidence, and patient experience more effectively.
Chelsey highlighted the growing discussion around MFN pricing and IRP, including what these developments could mean for manufacturers’ global launch and pricing strategies across North America and Europe. She also highlighted AI momentum, with large language models, natural language processing, machine learning, and agentic models gaining traction across HEOR, RWE, and market access.
Chelsey highlighted the growing discussion around MFN pricing and IRP, including what these developments could mean for manufacturers’ global launch and pricing strategies across North America and Europe. She also highlighted AI momentum, with large language models, natural language processing, machine learning, and agentic models gaining traction across HEOR, RWE, and market access.
Finally, she emphasized patient experience as a critical area of focus, with more attention being paid to outcomes beyond traditional clinical trial endpoints and HEOR studies. As digital transformation expands access to telemedicine, patient portals, and patient-centric data, the opportunity is growing to better understand and improve the full patient journey.
Where evidence strategy meets access reality
After decades of watching ISPOR evolve, Tommy Bramley, SVP, Global Consulting, Cencora, sees the next shift coming into sharper focus. At this year’s conference, he reflected on how the field has expanded from a strong methodological foundation into a broader conversation shaped by AI, MFN pricing, and the growing need to connect evidence generation more directly to patient access.
Tommy emphasized that the next wave of progress will depend on using data more effectively across the product lifecycle. He pointed to advances in data extraction, interpretation, and RWE as key enablers for building stronger models, understanding the patient journey more clearly, and identifying which patients are most likely to benefit from therapy.
Tommy emphasized that the next wave of progress will depend on using data more effectively across the product lifecycle. He pointed to advances in data extraction, interpretation, and RWE as key enablers for building stronger models, understanding the patient journey more clearly, and identifying which patients are most likely to benefit from therapy.
He also underscored the importance of developing evidence packages earlier, closing evidence gaps with the right methodologies, and aligning regulatory, health technology assessment (HTA), payer, and provider expectations more effectively. In a pricing environment shaped by MFN pressures, he noted that reducing uncertainty around launch sequencing and reimbursement strategy is critical to helping manufacturers bring therapies to more markets while supporting patient access. Ultimately, he framed the goal clearly: maximize patient benefit by accelerating innovation, optimizing access, and helping the right therapies reach the right patients at the right time.
The views and opinions expressed in this discussion represent the views and opinions of the participants and not Cencora and do not constitute legal advice.
